CompletedPhase 2NCT00932971
HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis
Studying Hepatitis delta
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- HepNet Study House, German Liverfoundation
- Principal Investigator
- Michael P. Manns, Prof. Dr.Hannover Medical School
- Intervention
- PEG-IFN alfa-2a, Tenofovir(drug)
- Enrollment
- 70 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2017
Study locations (10)
- Charité Campus Virchow-Klinikum, Med. Klinik für Gastroenterologie und Hepatologie, Berlin, Germany
- Friedrich-Wilhelms-Universität, Med. Klinik und Poliklinik I, Bonn, Germany
- Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Düsseldorf, Germany
- Klinikum der J.W. Goethe-Universität, Frankfurt, Germany
- Universitätsklinikum Hamburg-Eppendorf, Klinik für Innere Medizin, Hamburg, Germany
- Medizinische Hochschule Hannover, Zentrum Innere Medizin, Hanover, Germany
- Medizinische Fakultät der Universität Heidelberg, Innere Medizin IV, Heidelberg, Germany
- Athens University School of Medicine, Hippokration General Hospital, Athens, Greece
- Institutul de Boli Infectioase "Prof. Dr. Matei Bals", Bucharest, Romania
- Spitalul Clinic de Boli Infectioase si, Timișoara, Romania
Collaborators
Hannover Medical School · Hoffmann-La Roche · Gilead Sciences
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00932971 on ClinicalTrials.govOther trials for Hepatitis delta
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07454837Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideMirum Pharmaceuticals, Inc.
- RECRUITINGNCT07491848Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+DResearch Center of Periodontal-Systemic Interactions
- RECRUITINGPHASE3NCT07298330A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)Mirum Pharmaceuticals, Inc.
- RECRUITINGNCT07317011"Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGNCT07429864Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With BulvertideFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE3NCT07200908A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)Mirum Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT07142811A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionVir Biotechnology, Inc.
- RECRUITINGPHASE1, PHASE2NCT07096193Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta VirusGilead Sciences